Delving into the Latest Updates on Recombinant oncolytic virus M1(Guangzhou Vitron) with Synapse

Overview

Basic Info

Drug Type

Oncolytic virus

Synonyms

Recombinant oncolytic virus M1-c6v1, Recombinant oncolytic virus based on the backbone of Alphavirus M1

+ [5]

Target-

Action

stimulants

Mechanism

Cell death stimulants

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Pancreatic carcinoma non-resectableSolid tumorLocally Advanced Malignant Solid Neoplasm+ [5]

Inactive Indication

Metastatic hepatocellular carcinoma

Originator Organization

Guangzhou Virotech Pharmaceutical Co Ltd.

Active Organization

Guangzhou Virotech Pharmaceutical Co Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

RegulationOrphan Drug (United States)

Login to view timeline

The antigenic variation of influenza virus represents a major health problem, thus continuous efforts have been made to develop broad-spectrum vaccines against influenza virus. Matrix protein 1 (M1) protein is highly conserved in all influenza A strains. In this study, M1 protein was efficiently expressed in Escherichia coli (E. coli), then purified and used for immunization of BALB/c mice by intranasal drip using chitosan as adjuvant. The M1 protein was administered intranasally to mice in combination with chitosan adjuvant twice at an interval of 3 weeks. Three weeks after the second immunization, the mice were challenged with a lethal dose (5×LD(50)) of A/Chicken/Jiangsu/7/2002 (H9N2) virus, PR8 (H1N1) virus and A/Chicken/Henan/12/2004 (H5N1) virus. The protective immunity of the vaccine was evaluated by determining the survival rates, residual lung virus titers, bodyweight, and the serum antibody titers of the mice. The results showed that nasal administration of 100μg M1 in combination with chitosan could not only completely protect the mice effectively against the challenge of the homologous virus but also protect 70% and 30% of the mice against the heterologous H1N1 and H5N1 viruses, respectively. The study indicated that the M1 protein was a candidate antigen for a broad-spectrum influenza virus vaccine and the adjuvant chitosan significantly improved the efficacy of the M1 vaccine.

100 Deals associated with Recombinant oncolytic virus M1(Guangzhou Vitron)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic carcinoma non-resectable	Phase 2	China	Guangzhou Virotech Pharmaceutical Co Ltd.	12 Mar 2025
Solid tumor	Phase 1	-	Guangzhou Virotech Pharmaceutical Co Ltd.	01 Mar 2025
Locally Advanced Malignant Solid Neoplasm	Phase 1	Japan	Guangzhou Virotech Pharmaceutical Co Ltd.	10 Jul 2024
Hepatocellular Carcinoma	Phase 1	China	Guangzhou Virotech Pharmaceutical Co Ltd.	29 Apr 2024
Melanoma	Phase 1	China	Guangzhou Virotech Pharmaceutical Co Ltd.	29 Apr 2024
Prostatic Cancer	Phase 1	China	Guangzhou Virotech Pharmaceutical Co Ltd.	29 Apr 2024
Uterine Cervical Cancer	Phase 1	China	Guangzhou Virotech Pharmaceutical Co Ltd.	29 Apr 2024
Metastatic Solid Tumor	IND Approval	China	Guangzhou Virotech Pharmaceutical Co Ltd.	29 Nov 2023
Metastatic hepatocellular carcinoma	Discovery	-	Guangzhou Virotech Pharmaceutical Co Ltd.	25 Jan 2021